Pain Therapeutics Gets a Complete Response Letter From the FDA Stating, 'The Data Submitted in [the] NDA Do Not Support the Conclusion That the Benefits of [REMOXY] Extended-Release Capsules Outweigh the Risks'
Benzinga Newsdesk